J2062 HCPCS code: Loxapine for inhalation, 1 mg
J2062 is the HCPCS Level II code for loxapine for inhalation, 1 mg. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 10 per day on outpatient hospital claims.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2019-01-01 |
| Last action effective | 2024-01-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 10 | Prescribing Information |
| practitioner claims | 10 | Prescribing Information |
What changed for J2062
- 2019-01-01: J2062 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2062?
J2062 is the HCPCS Level II code for loxapine for inhalation, 1 mg. Short descriptor: "Loxapine for inhalation 1 mg".
Does Medicare cover J2062?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J2062 can be billed per day?
10 on outpatient hospital claims; 10 on practitioner claims (NCCI medically unlikely edits).
Related J20 codes
- J2001 — Injection, lidocaine hcl for intravenous infusion, 10 mg
- J2002 — Injection, lidocaine hcl in 5% dextrose, 1 mg
- J2003 — Injection, lidocaine hydrochloride, 1 mg
- J2004 — Injection, lidocaine hcl with epinephrine, 1 mg
- J2010 — Injection, lincomycin hcl, up to 300 mg
- J2020 — Injection, linezolid, 200 mg
- J2021 — Injection, linezolid (hospira), not therapeutically equivalent to j2020, 200 mg
- J2060 — Injection, lorazepam, 2 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2062
- Watch J2062 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2062
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.